0001209191-17-059632.txt : 20171107 0001209191-17-059632.hdr.sgml : 20171107 20171107171129 ACCESSION NUMBER: 0001209191-17-059632 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171107 FILED AS OF DATE: 20171107 DATE AS OF CHANGE: 20171107 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Thistle Mary CENTRAL INDEX KEY: 0001317917 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37601 FILM NUMBER: 171184334 MAIL ADDRESS: STREET 1: C/O VIACELL, INC. STREET 2: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dimension Therapeutics, Inc. CENTRAL INDEX KEY: 0001592288 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463942159 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-401-0011 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-11-07 1 0001592288 Dimension Therapeutics, Inc. DMTX 0001317917 Thistle Mary C/O DIMENSION THERAPEUTICS, INC. 840 MEMORIAL DRIVE, 4TH FLOOR CAMBRIDGE MA 02139 0 1 0 0 Chief Operating Officer Stock Option (Right to Buy) 3.57 2017-11-07 4 D 0 27711 D 2025-04-28 Common Stock 27711 0 D Stock Option (Right to Buy) 3.57 2017-11-07 4 D 0 180815 D 2025-04-28 Common Stock 180815 0 D Stock Option (Right to Buy) 4.09 2017-11-07 4 D 0 17104 D 2025-06-02 Common Stock 17104 0 D Stock Option (Right to Buy) 7.14 2017-11-07 4 D 0 65000 D 2026-01-31 Common Stock 65000 0 D Stock Option (Right to Buy) 1.90 2017-11-07 4 D 0 60000 D 2027-01-31 Common Stock 60000 0 D This stock option, which vests over four years beginning February 2, 2015, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. This stock option, which vests over four years beginning February 2, 2015, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. This stock option, which vested 2,494 shares on February 2, 2016, and vests in 41 equal monthly installments thereafter, beginning February 3, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. This stock option, which vests in 48 equal monthly installments beginning January 27, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. This stock option, which vests in 48 equal monthly installments beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. /s/ Mary Thistle 2017-11-07